Global Leukemia Academy
Emerging and Practical Concepts and Controversies in Leukemias
Overview
In recent years progress in the molecular understanding of acute leukemias has led to greatly improved comprehension of these diseases, and novel approved therapies are changing treatment paradigms. Aptitude Health has developed the Global Leukemia Academy and is organizing a series of meetings in 2020 to help physicians better understand how the emerging therapies and concepts are being adapted globally, and to address barriers between innovation and implementation for patient care.
Date and Location
23–24 July 2020
Virtual Meeting
Meeting Content
View the slides and watch the video of the Day 1
ALL Plenary Session
Faculty
Patrick A. Brown, MD
Johns Hopkins University
School of Medicine, USA
Roberta Demichelis, MD
Instituto Nacional de Ciencias
Médicas y Nutrición Salvador
Zubirán, Mexico
Lia Gore, MD
University of Colorado
Anschutz, Medical Campus, USA
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, USA
Franco Locatelli, MD, PhD
University of Rome
IRCCS Ospedale Pediatrico
Bambino Gesù, Italy
Aaron Logan, MD, PhD
University of California,
San Francisco, USA
Eduardo Rego, MD
University of São Paulo, Brazil
|
Agenda |
The virtual program ran over 2 days. Day 1: Plenary Session ALL Day 2: Parallel breakout sessions – Pediatric and Adult ALL |
| DAY 1: Virtual Plenary sessions | Time UTC-3 | Title | Speaker |
| Thursday, 23 July 2020 from 17.00 – 21.00 (UTC-3) |
17.00 – 17.10 | Welcome and meeting overview; introduction to the voting system | Elias Jabbour, Eduardo Rego |
| 17.10 – 17.25 | Review of prognostic value of MRD in ALL | Elias Jabbour | |
| 17.25 – 17.40 | How and when to check for MRD in ALL | Eduardo Rego | |
| 17.40 – 17.55 | MRD assessment and management in CR1 vs CR2 and beyond | Aaron Logan | |
| 17.55 – 18.10 | Genetic variants in ALL – Ph+ and Ph-like | Elias Jabbour | |
| 18.10 – 18.25 | AYA ALL patients – what is the current treatment approach for this diverse patient population? | Patrick Brown | |
| 18.25 – 18.45 | Break | ||
| 18.45 – 19.00 | Bispecific T-cell engagers as post-reinduction therapy improves survival in pediatric and AYA B-ALL | Patrick Brown | |
| 19.00 – 19.45 | Panel discussion on the role of HSCT • Experience of HSCT in the region • Pros, cons of HSCT; COVID-19 – impact and measures • Discussion and voting |
Eduardo Rego Aaron Logan All faculty |
|
| 19.45 – 20.25 | Debate on CD19-targeted approaches • CAR T • Monoclonal antibodies and bispecifics • Discussion and voting/td> |
Patrick Brown Elias Jabbour All faculty |
|
| 20.25 – 20.55 | Emerging data and the management of ALL patients during COVID-19 • Presentation • Panel discussion |
Elias Jabbour All faculty |
|
| 20.55 – 21.00 | Session close | Elias Jabbour, Eduardo Rego |
| DAY 2: Virtual Breakout 1: Pediatric ALL patients | Time UTC-3 | Title | Speaker |
| Friday, 24 July 2020 from 17.00 – 19.10 (UTC-3) | 17.00 – 17.15 | Session open • Educational ARS questions for the audience |
Patrick Brown |
| 17.15 – 17.35 | First-line treatment of pediatric ALL • Presentation • Q&A |
Lia Gore | |
| 17.35 – 17.55 | Current treatment options for relapsed ALL in children, including HSCT and COVID-19 considerations • Presentation • Q&A |
Franco Locatelli | |
| 17.55 – 18.15 | Bispecific T-cell engagers for pediatric ALL • Presentation • Q&A |
Patrick Brown | |
| 18.15 – 18.55 | Case-based panel discussion Management of long- and short-term toxicities and treatment selection in pediatric patients Panelists: María Sara Felice (Arg), Oscar González Ramella (Mex), Adriana Seber (Bra), Carlos Andres Portilla (Col) |
María Sara Felice Carlos Andres Portilla All panelists |
|
| 18.55 – 19.10 | Session close • Educational ARS questions for the audience |
Patrick Brown |
| DAY 2: Virtual Breakout 2: Adult ALL patients | Time UTC-3 | Title | Speaker |
| Friday, 24 July 2020 from 17.00 – 19.00 (UTC-3) |
17.00 – 17.15 | Session open • Educational ARS questions for the audience |
Elias Jabbour, Eduardo Rego |
| 17.15 – 17.35 | Optimizing first-line therapy in adult and older ALL – integration of immunotherapy into frontline regimens • Presentation • Q&A |
Elias Jabbour | |
| 17.35 – 17.55 | Current treatment options for relapsed ALL in adult and elderly patients • Presentation • Q&A |
Aaron Logan | |
| 17.55 – 18.45 | Case-based panel discussion Management of long- and short-term toxicities and treatment selection in adult and elderly patients Panelists: Elias Jabbour, Eduardo Rego, Aaron Logan, Roberta Demichelis |
Roberta Demichelis Eduardo Rego All panelists |
|
| 18.45 – 19.00 | Session close • Educational ARS questions for the audience |
Elias Jabbour, Eduardo Rego |
